Tafluprost — Membership Pricing
Tafluprost is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Tafluprost Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $106.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Tafluprost
Tafluprost is a prescription medication. Ask your doctor if Tafluprost is right for you.
How to Check Tafluprost Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Tafluprost at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Ophthalmology
About Tafluprost
Tafluprost is a vital prescription eye drop used to treat conditions like open-angle glaucoma and ocular hypertension, effectively reducing elevated intraocular pressure. Managing chronic conditions often comes with significant prescription costs, but TheDrugClub is dedicated to making essential medications like tafluprost more affordable. Discover how our membership can help you save on your eye care needs.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Tafluprost is approved for (FDA label)
Tafluprost ophthalmic solution is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Tafluprost ophthalmic solution is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: August 15, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Tafluprost (FDA label)
Ophthalmic solution: 0.0015% tafluprost in a single-dose container. Ophthalmic solution: 0.0015% tafluprost in a single-dose container. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: bfffa484-4105-45ec-ab1d-124e96639f35. SPL document ID: 9cf17449-54f5-49c2-93ea-c2be06bf56cd. Label effective date: August 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Tafluprost (FDA label)
Most common ocular adverse reaction is conjunctival hyperemia (4% to 20%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Preservative-containing or non-preserved tafluprost 0.0015% was evaluated in 905 patients in five controlled clinical studies of up to 24-months duration. The most common adverse reaction observed in patients treated with tafluprost was conjunctival hyperemia which was reported in a range of 4% to 20% of patients.
Source: FDA prescribing information (DailyMed). Set ID: bfffa484-4105-45ec-ab1d-124e96639f35. SPL document ID: 9cf17449-54f5-49c2-93ea-c2be06bf56cd. Label effective date: August 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Tafluprost (FDA label)
None. None. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: bfffa484-4105-45ec-ab1d-124e96639f35. SPL document ID: 9cf17449-54f5-49c2-93ea-c2be06bf56cd. Label effective date: August 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Tafluprost (FDA label)
• Pigmentation: Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. ( 5.1 ) • Eyelash Changes: Gradual changes to eyelashes including increased length, thickness and number of lashes. Usually reversible. ( 5.2 ) 5.1 Pigmentation Tafluprost ophthalmic solution has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Pigmentation is expected to increase as long as tafluprost is administered. The pigmentation change is due to increased melanin content in the melanocytes rather than to an increase in the number of melanocytes. After discontinuation of tafluprost, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients.
Source: FDA prescribing information (DailyMed). Set ID: bfffa484-4105-45ec-ab1d-124e96639f35. SPL document ID: 9cf17449-54f5-49c2-93ea-c2be06bf56cd. Label effective date: August 15, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.